Immunization Update, September 2007, Vol. 1, no. 6 by unknown
1 
 
Jim Goodrich, Chief 
Bureau of Disease Prevention and 
Immunization  
● 
Don Callaghan, Manager 
Immunization Program   
To be added to this newsletter mail-
ing list  please e-mail 
bkonz@idph.state.ia.us with your 
contact information. 
September  2007 
 
Iowa’s  
Immunization  
Registry Information  
System (IRIS)  
Enroll Today! 
 
Call the IRIS  
Help Desk at 
 1-800-374-3958  
for Enrollment Details or 
IRIS Questions. 
Inside This Issue 
New ACIP Recommendations 2 
Schools and IRIS-CS 2 
Travel Health and  
Immunizations 
3 
The Road to VMBIP 4 
Spotlight Topic:   
Needle Length 
5 
Adolescents and Tdap 6 
Health care workers (HCW) can spread 
the highly contagious influenza virus to 
patients in their care.  Influenza kills an 
average of 36,000 persons, 90 percent of 
whom are elderly, and hospitalizes over 
114,000 in the U.S. annually.   
Unvaccinated HCW can be a key cause of 
outbreaks in health care settings. These 
employees encounter high-risk patients 
throughout the influenza season in 
medical practices, general hospitals, 
specialty hospitals, long-term care and 
rehabilitation facilities, home-
care sites and other health care 
settings. 
CDC recommends all 
personnel (including 
volunteers) in hospitals, 
outpatient, and home-health 
settings who have any 
patient contact receive the 
influenza vaccine each fall to 
prevent transmission of 
influenza.  
Trivalent inactivated influenza 
vaccine (TIV) is preferred over 
live attenuated influenza vaccine 
(LAIV) for HCW who are in close 
contact with severely 
immunosuppressed persons 
when patients require a 
protective environment (e.g., 
stem cell transplant patients).  
To assist in your facility’s efforts to 
increase influenza vaccination among 
HCW, IDPH has posters and print 
materials you may order free of charge 
or download from the IDPH flu Web page 
(see page four for ordering information 
for IDPH program print materials). 
Additionally, the CDC and American Lung 
Association have comprehensive 
influenza campaign materials that can be 
used at your facility at no charge (see 
box below). 
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Influenza Vaccination:  Are YOU In Line? 
CDC—Flu Gallery: 
http://www.cdc.gov/flu/pro
fessionals/patiented.htm 
Immunization Action 
Coalition: 
http://www.immunize.org/ 
American Lung Associa-
tions “Faces of Influ-
enza” campaign: 
http://www.lungusa.org 
 
 IDPH Flu Page: 
http://www.idph.state.ia.us
/adper/flu.asp 
 
 
 
IDPH Immunization 
Page: 
 
http://www.idph.state.ia.us
/adper/immunization.asp 
 
No-Cost Influenza Resources 
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The Advisory Committee on Immuni-
zation Practices (ACIP) met on June 
27-28, 2007.  The ACIP meets three 
times annually and provides recom-
mendations to the Director of the 
CDC and the Secretary of the Depart-
ment of Health and Human Services 
(HHS) concerning the prevention of 
vaccine-preventable diseases in the 
United States.  
Following are summaries of key votes 
from the meeting.  These recommen-
dations become official when they 
are published in the Morbidity and 
Mortality Weekly Report (MMWR). To 
search for MMWRs go to: 
http://www.cdc.gov/mmwr/about.html 
Meningococcal Conjugate Vac-
cine:  The ACIP voted to recommend 
that all persons 11 through 18 years 
of age should be vaccinated against 
meningococcal disease.  
This recommendation would replace 
the current ACIP recommendation for 
routine vaccination with MCV4 of chil-
dren 11 through 12 years of age, 
New ACIP Recommendations 
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adolescents before high school entry 
(approximately 15 years of age), and 
other people at increased risk (such 
as college freshmen living in dorms.)  
An estimated 1,400 to 2,800 cases of 
meningococcal disease occur in the 
United States annually.   
Hepatitis A Vaccine (for Post-
Exposure Prophylaxis): The ACIP 
voted to recommend the option of 
using hepatitis A vaccine instead of 
immune globulin (IG) after exposure 
to hepatitis A virus (HAV).  
In deciding to use vaccine or IG, im-
munization providers should take into 
account patient characteristics associ-
ated with more severe manifestations 
of HAV, including older age and 
chronic liver disease. Also, the magni-
tude of the risk of HAV transmission 
from the exposure should be consid-
ered.   
Generally, hepatitis A vaccine is pre-
ferred for healthy persons 12 months 
to 40 years of age, and IG for persons 
40 years of age and older.  
While rates of HAV have declined 
dramatically in the United States 
since 2000, the need for post-
exposure prophylaxis remains. 
Adult Immunization Schedule:  
The ACIP approved the new Adult 
Immunization Schedule (October 
2007-September 2008) to reflect 
current recommendations for use of 
licensed vaccines in people 19 years  
of age and older.  Changes include 
the addition of zoster vaccine to the 
schedule.  
ACIP annually reviews the recom-
mended Adult Immunization Sched-
ule.  This schedule is also approved 
by the American Academy of Family 
Physicians (AAFP), the American 
College of Obstetricians and Gyne-
cologists (ACOG), and the American 
College of Physicians (ACP). Ap-
proximately 43,000 adults in the 
United States die each year from 
vaccine-preventable diseases.  
(Continued on Page 3)    
In November 2007,  IDPH Im-
munization Program staff will 
be traveling throughout the 
state to an anticipated 16 sites 
to present Vaccine University.   
This curriculum is designed to teach vaccine storage and 
handling, Iowa immunization law, and Iowa VFC Program 
requirements.  Currently sessions are under construction; 
however, we expect that the training will be provided at 
no cost, half-day session, offering both nursing and certi-
fied medical assistant CEUs.  Successful post-testing will 
entitle a participant to be certified as a “Vaccine Univer-
sity graduate”.   
As planning continues, information including locations, 
times, agendas, and registration information will be 
mailed to VFC providers and posted on our Web page: 
(http://www.idph.state.ia.us/adper/immunization.asp) Get 
ready for Vaccine University 2007!  
SCHOOLS—Don’t Forget 
to Sign Up for IRIS-CS! 
 
The view-only version of IRIS, called the Immu-
nization Registry Information System – Certifi-
cate Search (IRIS-CS), is now available.   
IRIS-CS allows schools to search, view 
and print the Certificate of Immuniza-
tion. Using IRIS-CS will provide schools 
with required immunization information 
without added work on behalf of school 
personnel, parents, and health care pro-
viders.  
 Enroll today! Visit the IRIS Web site to 
obtain the IRIS-CS enrollment form, computer require-
ments, and frequently asked questions about IRIS-CS 
at www.idph.state.ia.us/adper/immunization_programs.asp#iris.   
For IRIS-CS questions, please call the IRIS Help Desk at 
1-800-374-3958. 
Vaccine University 2007 
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New ACIP Recommendations,  Continued 
Prevention of Influenza: A new 
report published in CDC’s MMWR 
updates the 2006 influenza recom-
mendations of the ACIP for preven-
tion and control of influenza. Esti-
mated vaccination coverage remains 
less than 50 percent among certain 
groups for whom routine annual 
vaccination is recommended, includ-
ing young children and adults with 
risk factors for influenza complica-
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tions, health-care workers (HCW), 
and pregnant women.  
Strategies to improve vaccination cov-
erage, including use of reminder/  
recall systems and standing orders 
programs, should be implemented or 
expanded. The 2007 recommenda-
tions to improve vaccination coverage 
include new and updated information 
(see highlighted box). 
The full report and other information 
is available at CDC’s influenza web-
site (www.cdc.gov/flu). Updates or 
supplements to these recommenda-
tions (e.g., expanded age or risk 
group indications for currently li-
censed vaccines) might be required.  
Immunization providers should check 
the CDC influenza Web site periodi-
cally for additional information. 
Strategies to improve vaccination coverage, including use of reminder/recall systems and standing orders programs, 
should be implemented or expanded. The 2007 recommendations include new and updated information, specifically: 
1. Reemphasizing the importance of administering 2 doses of vaccine to all children aged 6 months–8 years if they have 
not been vaccinated previously at any time with either live, attenuated influenza vaccine (for healthy children over 5 
years of age; doses separated by >6 weeks) or trivalent inactivated influenza vaccine (doses separated by >4 weeks), 
with single annual doses in subsequent years. 
2. Recommending that children aged 6 months–8 years who received only 1 dose in their first year of vaccination receive 
2 doses the following year, with single annual doses in subsequent years. 
3. Highlighting a previous recommendation that all persons, including school-aged children, who want to reduce the risk 
of becoming ill with influenza or of transmitting influenza to others should be vaccinated. 
4. Emphasizing that immunization providers should offer influenza vaccine and schedule immunization clinics throughout 
the influenza season. 
5. Recommending that health-care facilities consider the level of vaccination coverage among HCW to be one measure of 
a patient safety quality program and implement policies to encourage HCW vaccination (e.g., obtaining signed state-
ments from HCW who decline influenza vaccination). 
6. Using the 2007–2008 trivalent vaccine virus strains A/Solomon Islands/3/2006 (H1N1)-like (new for this season), 
A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. 
The CDC Yellow Book, entitled CDC 
Health Information for International 
Travel 2008, is now available online 
at http://wwwn.cdc.gov/travel 
The Yellow Book, published 
every two years, is written pri-
marily for health care providers. 
Hard copies of the Yellow Book 
are available for sale at most 
major bookstores or can be pur-
chased online at 
www.us.elsevierhealth.com/product.jsp?is
bn=9780323048859. 
In addition, the CDC Travelers’ 
Health Web site (above) has long 
provided information, based on sci-
entific studies, disease surveillance, 
and best practices, to assist travelers 
and their health care provid-
ers in deciding the vaccines, 
medications, and other 
measures necessary to pre-
vent illness and injury during 
international travel.  
In response to requests from  
users, the site has been up-
dated to provide travel health infor-
mation by country (destination). 
These new destination pages provide 
detailed information about disease 
risks, including country-specific 
malaria recommendations and yel-
low fever vaccine recommenda-
tions and requirements for individ-
ual countries and destinations. In 
addition, every page on the site 
has a new printer-friendly option, 
allowing users to print pages in an 
easy-to-read format.  
Please note that the URLs for the 
Travelers’ Health Web pages have 
changed.  Please visit the new 
Travelers Health site at 
http://wwwn.cdc.gov/travel/defaul
t.aspx.  
Travel Health and Immunizations 
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The Vaccine Management Business 
Improvement Project (VMBIP) repre-
sents efforts of the CDC and the Na-
tional Center for Immunization and 
Respiratory Diseases (NCIRD) to im-
prove current vaccine management 
processes at the federal, state, and 
local levels.   The specific goals of 
VMBIP are to: 
• Simplify processes for ordering, 
distributing, and managing vac-
cines in order to respond more 
quickly and effectively to public 
health crises related to disease 
outbreaks, vaccine shortages, 
and disruption of the vaccine 
supply. 
• Implement a more efficient vac-
cine supply system that will result 
in redirecting vital public health 
resources away from vaccine dis-
tribution and toward public 
health activities that will improve 
immunization coverage levels. 
• Enable the direct delivery of vac-
cines to providers.   
 
To achieve these goals the nation will 
transition to third party vaccine distri-
bution for all vaccines purchased 
through the federal vaccine contracts.   
In December 2007 Iowa will transition 
to a third party distributor, McKesson 
General Medical, to ship all vaccine.  
As part of the transition process, 
IDPH will begin to scale back its on-
hand vaccine supply in late fall in 
preparation for the December “go 
live” date. Once this occurs, IDPH will 
no longer maintain or ship vaccines.  
McKesson General Medical will man-
age warehousing and distribution of 
all vaccines previously ordered 
through IDPH.   
Currently, it is projected to take one 
week for McKesson to process and 
distribute vaccine orders.   
Prior to implementing VMBIP in 
Iowa, one of the most important 
things providers can do is assess 
vaccine storage capacity.  IDPH 
plans to survey Vaccines for Chil-
dren (VFC) providers to obtain a 
clearer picture of storage capacity in 
the state.  Once information on stor-
age capacity is obtained it will be 
made available to McKesson for fu-
ture use to determine vaccine order-
ing capacity and ordering frequency.   
As this project moves forward, IDPH 
will continue to share progress on 
this exciting endeavor.     
 
Please contact Don Callaghan at 1-
800-831-6293, ext 1 with questions.   
The Road to VMBIP 
IDPH Immunization Program  
Brochures Updated! 
 
The Immunization Program has updated all 
the brochures with the Immunize for a Bet-
ter Life theme.  The revised brochures have 
a date of 05/07 on the back in light gray 
(see sample to the right).   
Please take a moment to review your bro-
chure supply and request the most current 
brochures for your clients.  Remember that 
we have influenza brochures and posters available too!  
A complete list of Immunization Program materials is avail-
able on the Immunization Program Web page at 
www.idph.state.ia.us/adper/common/pdf/immunization/literature_order_form.pdf.  
Materials maybe ordered free of charge from the Health Protec-
tion Clearinghouse by:  
1. Calling Toll Free 1-888-398-9696  
2. Faxing your order form to (319) 861-2869 
3. E-mail clrhouse@crlibrary.org, or 
4. Mailing the order form to: Health Protection Clearinghouse, 
615 5th Street SE, Cedar Rapids, IA 52401  
2007 Immunization  
Conference Summary:  
Thank you to all the partici-
pants who helped to make the 
2007 Immunization Confer-
ence:  Immunize for a Better 
Life, a success!   
We are proud to have hosted 
one of the largest immuniza-
tion conferences in our region 
which included almost 700 par-
ticipants from across Iowa and 
several neighboring states!   
Planning has already begun for 
the 2009 conference and we 
hope to see you there.  If you 
have any suggestions for the 
next statewide conference, 
please contact Bridget Konz at 
1-800-831-6293 or 
bkonz@idph.state.ia.us. 
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Spotlight Topic:  Needle Length 
 
 
Choosing needle length for immuni-
zations is important.  Vaccine must 
reach the desired tissue site for 
optimal immune response. 
Therefore, needle selection should 
be based upon the prescribed 
route, size of the individual, volume 
and viscosity of the vaccine, and 
injection technique. 
Subcutaneous (Sub-Q or SC) in-
jections are administered into the 
fatty tissue found below the dermis 
and above muscle tissue.   
Subcuta-
neous 
tissue can 
be found 
all over 
the body. 
The usual 
sites for 
vaccine 
admini-
stration 
are the thigh (for infants <12 
months of age) and the upper 
outer triceps of the arm (for per-
sons >12 months of age). If neces-
sary, the upper outer triceps area 
can be used to administer subcuta-
neous injections to infants. 
Needle Gauge & Length: 5/8-
inch, 23 to 
25 gauge 
needle is 
needed for 
Sub-Q in-
jections. 
 
 
 
Intramuscular (IM) injections are 
administered into muscle tissue be-
low the dermis and subcutaneous 
tissue. 
 
 
 
 
 
 
Needle Gauge: 22 to 25 gauge nee-
dle.  For all intramuscular injections, 
the needle should be long enough to 
reach the muscle mass and prevent 
vaccine from seeping into subcutane-
ous tis-
sue, but 
not so 
long as 
to in-
volve 
underly-
ing 
nerves, 
blood 
vessels, 
or bone. 
Infants (Younger Than 12 
Months):  For the majority of in-
fants, the anterolateral aspect of the 
thigh is the recommended site for 
injection because it provides a large 
muscle mass.  
The muscles of the buttock have not 
been used for administration of vac-
cines in infants and children because 
of concern about potential injury to 
the sciatic nerve, which is well docu-
mented after injection of antimicro-
bial agents into the buttock.  
Injection technique is the most im-
portant factor to ensure efficient in-
tramuscular vaccine delivery. If the 
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subcutaneous and muscle tissue are 
bunched to minimize the chance of 
striking bone, a 1-inch needle is re-
quired to ensure intramuscular ad-
ministration in infants. For the major-
ity of infants, a 1-inch, 22-25-gauge 
needle is sufficient to penetrate mus-
cle in an infant's thigh. For newborn 
(first 28 days of life) and premature 
infants, a 5/8 inch needle usually is 
adequate if the skin is stretched flat 
between thumb and forefinger and the 
needle inserted at a 90-degree angle 
to the skin. 
Toddlers and Older Children (12 
Months through 10 Years): The 
deltoid muscle should be used if the 
muscle mass is adequate. The needle 
size for deltoid site injections can 
range from 22 to 25 gauge and from 
5/8 to 1 inch on the basis of the size 
of the muscle and the thickness of 
adipose tissue at the injection site.  
A 5/8-inch needle is adequate only for 
the deltoid muscle and only if the skin 
is stretched flat between thumb and 
forefinger and the needle inserted at a 
90° angle to the skin. For toddlers, 
the anterolateral thigh can be used, 
but the needle should be at least 1 
inch in length. 
Adolescents and Adults (11 Years 
or Older): For adults and adoles-
cents, the deltoid muscle is recom-
mended for routine intramuscular vac-
cinations. The anterolateral thigh also 
can be used.  
For men and women weighing less 
than 130 lbs (60 kg) a 5/8-1 inch nee-
dle is sufficient to ensure intramuscu-
lar injection. For women weighing 
130-200 lbs (60-90 kg) and men 130-
260 lbs (60-118kg), a 1-1½-inch nee-
dle is needed. For women weighing 
more than 200 lbs (90 kg) or men 
weighing more than 260 lbs (118 kg), 
a 1½-inch needle is required. 
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In June 2005, the ACIP approved 
recommendations for the use of 
tetanus toxoid, reduced diphtheria 
toxoid and cellular pertussis vac-
cine (Tdap) in adolescents.  These 
recommendations were published 
in March 2006 (MMWR 2006;55) 
http://www.cdc.gov/mmwr/PDF/rr/
rr5503.pdf.   
National distribution trends and 
purchases through the CDC con-
tracts suggest that a significant 
proportion of tetanus toxoid, re-
duced diphtheria toxoid vaccine 
(Td) is being purchased for routine 
use in adolescents.  The informa-
tion below serves as a re-
minder for the recommended 
use of Tdap vaccine in adoles-
cents.  ACIP currently recom-
mends: 
• Adolescents aged 11 through 
18 years should receive a sin-
gle dose of Tdap instead of Td 
for the routine adolescent 
booster immunization, and 
• Adolescents aged 11 through 
18 years who received Td, but 
not Tdap, are encouraged to 
receive a single dose of Tdap 
to provide protection against 
pertussis. An interval of at least 
five years between Td and 
Tdap is encouraged to reduce 
the risk for local and systemic 
reactions after Tdap vaccina-
tion. However, an interval less 
than five years between Td and 
Tdap can be used. 
Exceptions to the routine use of 
Tdap vaccine includes those who 
have not completed the recom-
mended childhood primary vaccina-
tion series with diphtheria and teta-
nus toxoids and whole cell pertussis 
vaccine (DTP)/ diphtheria and teta-
nus toxoids and acellular pertussis 
vaccine (DTaP).  
For those who require catch-up 
doses in this case, Tdap should be 
substituted for a single dose of Td 
and Td should be used for the other 
catch-up doses.   
Also, Tdap is contraindicated for 
adolescents with a history of en-
cephalopathy (e.g., coma or pro-
longed seizures) not attributable to 
an identifiable cause within seven 
days of administration of a vaccine 
with pertussis components. This 
contraindication is for the pertussis 
components and these persons 
should receive Td instead of Tdap.   
For more information, please see 
the published recommendations 
http://www.cdc.gov/mmwr/PDF/rr/r
r5503.pdf.   
The IDPH Immunization Program 
continues to receive calls regarding 
administration errors between Tdap 
and DTaP.  Recently sanofi pasteur 
changed the packaging of their pe-
diatric pertussis vaccine and their 
adolescent and adult pertussis vac-
cine packaging.   
Both ADACEL and DAPTACEL vac-
cine packaging have changed to 
reduce the possibility of confusing 
these two vaccines. Please note the 
following changes: 
 
Adolescents and Tdap 
• New package and label col-
ors: The new ADACEL vaccine 
tangerine color and DAPTACEL 
vaccine dark blue color packages 
and vial labels will clearly stand 
out in your refrigerators, reduc-
ing the chance of grabbing the 
wrong vaccine.   
• More distinct tabs on pack-
age: In addition to the different 
package colors, the generic 
“Tdap” and “DTaP” package tabs 
have new colors that better dif-
ferentiate the two packages.  
• Clear use descriptions next 
to package logos:  Each pack-
age identifies “For adolescent 
and adult use” next to the ADA-
CEL vaccine logo or “For pediatric 
use” next to the DAPTACEL vac-
cine logo.  
• Product Logos: Each package 
now contains the product logo 
for greater product differentia-
tion. 
We Want to Hear From You! 
Are there immunization related topics you want to know more about?  Is there someone you think 
would enjoy reading this newsletter and is not on our mailing list?  Please contact Bridget Konz at 
bkonz@idph.state.ia.us with your article suggestions or to request newsletters.  We want to hear 
from you! 
